Lung cancer is the leading cause of cancer-related mortality in western countries [1] 
highly expressed in a wide variety of normal cells, but the expression of decoy receptors is substantially limited in tumour cells
.
Treatment with TRAIL induces programmed cell death in a wide range of transformed cells, both in vitro and in vivo, without producing significant effects in normal cells [6, 7] . This unique property makes TRAIL an attractive candidate for cancer therapy. However, a significant proportion of cancer cell lines is resistant to TRAIL-induced apoptosis [8] . Apoptotic signalling could be opposed by enhanced expression of intracellular molecules acting at multiple levels [9, 10] [9, 11, 12] . PED inhibits the formation of a functional death-inducing signalling complex (DISC) and the activation of caspase 8, which take place following treatment with different apoptotic cytokines including CD95/FasL, TNF-␣ and TRAIL [9, [13] [14] [15] [16] . The anti-apoptotic action of PED is accomplished, at least in part, through its DED domain, which acts as a competitive inhibitor for pro-apoptotic molecules during the assembly of the DISC [9, 15] . PED is overexpressed in a number of different tumours, including human glioma [13] , squamous carcinoma [17] , breast cancer [18] and B-cell lymphocytic leukaemia [19] . We recently reported that human breast cancer cells express high levels of PED and that AKT/PKB activity regulates PED protein levels [18, 19] .
. Among these molecules is PED (phosphoprotein enriched in diabetes) (known also as PED/PEA-15), a death-effector domain (DED) family member of 15 kD involved in cell growth and metabolism

Furthermore, high PED expression levels determine resistance of breast cancer cells to chemotherapy-induced cell death.
In this study, we focused on the involvement of PED in determining the 'TRAIL-resistant phenotype ' 
Small interfering (si) RNAs
The [12] . (Fig. 5B) .
Tissue microarray construction and immunohistochemistry
Cylinders of 0.6-mm diameter were punched from donor blocks in areas identified as neoplastic after analysis of haematoxylin and eosin stained sections. The tissue cylinders were inserted into a recipient paraffin block using a precision instrument (Beecher
Results
PED expression in NSCLC tissue
The treatment of CALU-1 cells with a specific c-FLIPL siRNA down-regulated c-FLIPL expression but did not increase sensitivity to TRAIL-induced cell death (Fig. 5C). These data further confirm that PED protects lung cancer cells from TRAIL-induced apoptosis, and that inhibiting PED expression results in increased TRAIL sensitivity.
Effects of silencing PED on caspase activation in CALU-1 cells
We then examined the activation of caspase 8 
Effect of increasing PED expression on TRAIL sensitivity in H460 cells
To further evaluate the role of PED in apoptosis resistance, TRAILsensitive H460 cells were transfected with PED cDNA to up-regulate (Fig. 6C) rendered them resistant to TRAIL, as assessed by Western blotting for caspase 8 and PARP (Fig. 6B) or by a cell viability assay (Fig. 6D) .
PED protein levels and then analysed for their susceptibility to TRAIL-induced cell death. Increasing the expression of PED in these cells
Discussion
Increased expression of DED family members with anti-apoptotic functions, such as PED, represents a possible mechanism by which tumour cells escape apoptosis. PED acts primarily by preventing the interaction between the adaptor molecule, FADD, and
procaspase-8 [9, 15] . We have reported that PED inhibits the anti-apoptotic signal of death receptors in many different cell types, including breast carcinoma and glioma [9, [13] [14] [15] [16] [22] . Apoptosis-based anti-cancer therapies are designed to achieve tumour eradication through the [7, [23] [24] [25] . In fact, a number of biotech and pharmaceutical companies developed recombinant TRAIL/Apo2L as well as humanized agonistic mAb targeting TRAIL-R1 or TRAIL-R2 that are currently being evaluated in phase I and phase II clinical trails [7] . However, in a number of patients, tumour cells evade death signals generated by drugs through the activation of effective antiapoptotic mechanisms [26] [27] [28] [13] and B-cell chronic leukaemia [19] (Garofalo et al., in press) .
Mice that are genetically deficient in the TRAIL gene, exhibit increased susceptibility to experimental and spontaneous tumours [29] 
